Gloucester raises $29 million to fund lymphoma drug
This article was originally published in Scrip
Gloucester Pharmaceuticals of the US has raised $29 million in a series D financing. The proceeds will be used to fund the ongoing development of Istodax (romidepsin), a novel histone deacetylase (HDAC) inhibitor for the treatment of T-cell lymphomas and other haematological malignancies.
You may also be interested in...
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.